Intravenous Dofetilide, a Class III Antiarrhythmic Agent, for the Termination of Sustained Atrial Fibrillation or Flutter
Authors:
- Rodney H. FalkRFRodney H. Falk
- Arthur PollakAPArthur Pollak
- Steven N. SinghSSSteven N. Singh
- Tilman FriedrichTFTilman Friedrich
Open Access
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- To prolong refractoriness or to delay conduction (or both)?European Heart Journal, 1992
- Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation: Observations on the role of trial design and implications of drug-related mortalityAmerican Heart Journal, 1992
- Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutterThe American Journal of Cardiology, 1992
- Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.Circulation, 1990
- Rate-Dependent Class III Antiarrhythmic Action, Negative Chronotropy, and Positive Inotropy of a Novel Ik Blocking Drug, UK-68,798Journal of Cardiovascular Pharmacology, 1990
- Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.Journal of General Physiology, 1990
- When is QT prolongation antiarrhythmic and when is it proarrhythmic?The American Journal of Cardiology, 1989
- Digoxin for Converting Recent-Onset Atrial Fibrillation to Sinus RhythmAnnals of Internal Medicine, 1987
- Control of cardiac arrhythmias by selective lengthening of repolarization: Theoretic considerations and clinical observationsAmerican Heart Journal, 1985
- A Comparison of Some Approximate Confidence Intervals for the Binomial ParameterJournal of the American Statistical Association, 1979